Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Expansion Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects with Advanced And/or Metastatic Solid Tumors Known to Express C-Kit

Next Previous
Trial Profile

A Phase 1 Dose Escalation and Expansion Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects with Advanced And/or Metastatic Solid Tumors Known to Express C-Kit

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NN 3201 (Primary)
  • Indications Adenoid cystic carcinoma; Gastrointestinal stromal tumours; Neuroendocrine tumours; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Novelty Nobility

Most Recent Events

  • 13 Feb 2025 Status changed from not yet recruiting to recruiting.
  • 25 Dec 2024 New trial record
  • 19 Dec 2024 According to NoveltyNobility media release, This phase 1 clinical trial will be conducted in the United States from the second half of this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top